{"id":"NCT04368429","sponsor":"Sanofi","briefTitle":"Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age","officialTitle":"Immunogenicity and Safety of a Single Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-05-22","primaryCompletion":"2020-11-07","completion":"2020-11-07","firstPosted":"2020-04-29","resultsPosted":"2021-10-06","lastUpdate":"2023-09-26"},"enrollment":360,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Meningococcal Immunisation (Healthy Volunteers)"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate Vaccine)","otherNames":[]},{"type":"BIOLOGICAL","name":"Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine","otherNames":["Menactra®"]}],"arms":[{"label":"Group 1: MenACYW Conjugate Vaccine","type":"EXPERIMENTAL"},{"label":"Group 2: Menactra® vaccine","type":"ACTIVE_COMPARATOR"}],"summary":"Primary Objective:\n\nTo demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, Y, and W following the administration of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate vaccine) compared with those observed following the administration of a single dose of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra® vaccine).\n\nSecondary Objective:\n\nImmunogenicity: To describe the antibody responses to the meningococcal serogroups A, C, Y, and W before and 30 days (+14 days) after vaccination with MenACYW Conjugate vaccine or Menactra®.\n\nSafety: To describe the safety profile of MenACYW Conjugate vaccine and that of Menactra®.","primaryOutcome":{"measure":"Percentage of Participants With Vaccine Seroresponse For Meningococcal Serogroup A, C, Y And W Following Vaccination With MenACYW Conjugate and Menactra® Vaccine: Non-Inferiority Analysis","timeFrame":"Day 30 (post-vaccination)","effectByArm":[{"arm":"Group 1: MenACYW Conjugate Vaccine","deltaMin":85.6,"sd":null},{"arm":"Group 2: Menactra® Vaccine","deltaMin":65.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":20},"locations":{"siteCount":4,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":179},"commonTop":["Injection Site Pain","Myalgia","Headache","Malaise","Injection Site Erythema"]}}